Form 8-K · Current Report · Filed 2025-10-30
Metsera Declares Novo Nordisk Proposal as Superior Company Proposal
On October 29, 2025, Metsera, Inc.'s Board of Directors declared an unsolicited proposal from Novo Nordisk A/S as a 'Superior Company Proposal' under its Merger Agreement with Pfizer Inc.
- Filer
- MTSR MTSR
- Filed
- Accession
- 0001193125-25-257435
- CIK
- 0002040807
- Signal
- Low impact
- Source
- Official filing on sec.gov ↗
Details
The Novo Nordisk Proposal values Metsera at up to $77.75 per share, a total of approximately $9.1 billion. This triggers a negotiation period for Pfizer to adjust the terms of the Pfizer Merger Agreement. Metsera shareholders do not need to take any action at this time. The Pfizer Merger Agreement remains in effect.
Items reported
Other Events
Market reaction
Close before filing
$52.21
Next session
+20.7%
Since filing
+35.0%
Latest close
$70.50
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MTSR reporting the same item, with the next session's move:
Never miss another MTSR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.